- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on CD30-Positive Gray Zone Lymphoma
Total 5189 results
-
Abramson Cancer Center of the University of PennsylvaniaCompletedCD30-Positive Diffuse Large B-Cell Lymphoma | CD30 Positive Primary Mediastinal Large B-cell Lymphoma | CD30-Positive Gray Zone LymphomaUnited States
-
Eric Bernicker, MDMillennium Pharmaceuticals, Inc.; The Methodist Hospital Research InstituteWithdrawnCD30-positive Lymphoma | CD30-positive Solid TumorUnited States
-
Medical College of WisconsinMidwest Athletes Against Childhood CancerNot yet recruitingLymphoma | Leukemia | Hodgkin Disease | CD30-Positive Diffuse Large B-Cell Lymphoma | CD30+ Anaplastic Large Cell Lymphoma | CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma | CD30+ Immunoblastic Large T-Cell Cutaneous LymphomaUnited States
-
University of CologneUnknownCD30 Positive Cutaneous T Cell Lymphoma | CD30 Positive Transformed Mycosis FungoidesGermany
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Novartis PharmaceuticalsCompletedMantle Cell Lymphoma | Gray Zone Lymphoma | Hodgkin's Disease | CD20+, B-cell Lymphomas | Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL) | Transformed Lymphoma/DLBCL/PMBCLUnited States
-
The First Affiliated Hospital of Soochow UniversityShanghai Unicar-Therapy Bio-medicine Technology Co.,LtdUnknownRefractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | CAR - T CD19/CD20/CD22/CD30China
-
Seoul National University HospitalSeoul National University Bundang Hospital; SMG-SNU Boramae Medical CenterCompletedRelapsed or Refractory EBV-and CD30-positive LymphomasKorea, Republic of
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Lymphoma | CD20 Positive | Lymphocytic NeoplasmUnited States
-
Poitiers University HospitalCompleted
-
TakedaCompletedUntreated CD30-Positive Hodgkin's LymphomaJapan
-
Hospices Civils de LyonCompleted
-
University of WashingtonNational Cancer Institute (NCI)WithdrawnAnaplastic Large Cell Lymphoma, ALK-Positive | CD30-Positive Neoplastic Cells Present | Systemic Anaplastic Large Cell LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | CCND1 Positive | CCND2 Positive | CCND3 Positive | CD20 Positive | Refractory Mantle Cell LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Janssen, LPCompletedCD20 Positive | Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Ann Arbor Stage II Marginal Zone Lymphoma | Ann Arbor Stage III Marginal... and other conditionsUnited States
-
AbbVieGenentech, Inc.Active, not recruitingNon-Hodgkin's Lymphoma | Hematological Malignancies | Chronic Lymphoid Leukemia | CD20-Positive Lymphoid MalignanciesUnited States, Australia
-
University of ArizonaWithdrawnFollicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Mediastinal Large B-cell Lymphoma | Grey Zone Lymphoma | High Grade B Cell LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnMantle Cell Lymphoma | CCND1 Positive | CD20-Positive Neoplastic Cells Present
-
University of GiessenCompletedMarginal Zone Lymphomas | Non-Hodgkin Lymphomas | Follicular Lymphomas | Immunocytomas | Lymphocytic LymphomasGermany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma | CD20 Positive | T-Cell Non-Hodgkin LymphomaUnited States
-
Guangzhou Excelmab Inc.RecruitingSafety and Efficacy of EX103 in Subjects With Relapsed/Refractory CD20-Positive Non-Hodgkin LymphomaCD20-positive Non-Hodgkin LymphomaChina
-
Conjupro Biotherapeutics, Inc.SuspendedCD20 Positive Non Hodgkin LymphomaUnited States
-
Seoul National University HospitalGyeongsang National University Hospital; Hallym University Medical Center; Kyunghee...TerminatedCD20-positive Non-Hodgkin LymphomaKorea, Republic of
-
Jurgen BarthSponsor GmbHActive, not recruitingNon-Hodgkin's Lymphoma | Lymphocytic Lymphoma | Marginal Zone Lymphomas | Follicular Lymphomas | Immunocytomas | Mantle-Cell LymphomasGermany
-
Shanghai Henlius BiotechWithdrawnCD20-positive Follicular Lymphoma, With Low Tumour Burden
-
Zhejiang Teruisi Pharmaceutical Inc.RecruitingCD20-positive B-cell Non-Hodgkin LymphomaChina
-
National Cancer Institute (NCI)CompletedLymphoma | Diffuse Large B-Cell Lymphoma | Non-Hodgkin Lymphoma | Primary Central Nervous System Lymphoma | Gray-zone LymphomaUnited States
-
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.RecruitingStudy of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's LymphomaCD20-positive B-cell Non-Hodgkin's LymphomaChina
-
Shanghai Pharmaceuticals Holding Co., LtdCompletedCD20 Positive B Cell Non-Hodgkin's LymphomaChina
-
Beijing Mabworks Biotech Co., Ltd.CompletedCD20-positive B Cell Non-Hodgkin LymphomaChina
-
Janssen Research & Development, LLCPharmacyclics LLC.CompletedCD20-positive B-cell Non-Hodgkin LymphomaUnited States, France
-
Maria Sklodowska-Curie National Research Institute...KCRINot yet recruitingCD20-positive Acute Lymphoblastic LeukemiaPoland
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | CD20 Positive | Refractory Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | CCND1 Protein Overexpression | CD5 Positive | FCER2 Negative | Pleomorphic Variant Mantle Cell Lymphoma | t(11;14)(q13;q32)United States
-
Lymphoma Study AssociationTerminatedCD20-Positive Large B-Cell LymphomaFrance
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Not yet recruitingHodgkin Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Anaplastic Large Cell Lymphoma, ALK-negative | CD30-Positive Diffuse Large B-Cell Lymphoma | Anaplastic Large Cell Lymphoma, T Cell and Null Cell TypeUnited States
-
Lymphoma Study AssociationAmgenCompletedUntreated CD20-positive Large B-cell LymphomaFrance
-
The Lymphoma Academic Research OrganisationHoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma CD20 PositiveFrance, Belgium
-
University of ArizonaActive, not recruitingLymphoma, Follicular | Myelodysplastic Syndromes | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Marginal Zone Lymphoma | Acute Myelogenous Leukemia | Mantle-Cell Lymphoma | Chronic Myelogenous Leukemia | Lymphoma, Hodgkin | Gray Zone Lymphoma | Lymphoma,Non-Hodgkin | Large Cell Lymphoma | High Risk Undifferentiated...United States
-
Narendranath EpperlaNot yet recruitingRecurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnn Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Extranodal Marginal Zone LymphomaUnited States
-
National Cancer Institute (NCI)CompletedRefractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | CD20 PositiveUnited States
-
Fondazione Italiana Linfomi ONLUSTerminatedCD20 Positive Diffuse Large B-cell Lymphoma | Elderly Unfit PatientsItaly
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingMantle Cell Lymphoma | CD20 PositiveUnited States
-
Fujian Medical UniversityRecruitingRelapsed or Refractory DLBCL Patients With Either CD19 or CD20 PositiveChina
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditionsUnited States
-
M.D. Anderson Cancer CenterTakedaWithdrawnAnaplastic Large Cell Lymphoma | Classical Hodgkin Lymphoma | Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic | CD30+ Peripheral T-cell Lymphoma
-
University of WashingtonGenentech, Inc.RecruitingMarginal Zone Lymphoma | Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal Zone...United States
-
Emory UniversityTerminatedFollicular Lymphoma | Diffuse Large B-Cell Lymphoma | Myelofibrosis | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Acute Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Small Lymphocytic Lymphoma | Graft Versus Host Disease | Chronic Myelogenous Leukemia,...United States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Genentech, Inc.; Pharmacyclics LLC.RecruitingNon-Hodgkin's Lymphoma | Indolent Non-hodgkin Lymphoma | Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage II Nodal Marginal Zone Lymphoma | Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma | Ann Arbor... and other conditionsUnited States
-
Atara BiotherapeuticsRecruitingHigh-grade B-cell Lymphoma | MCL | Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements | Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma | LBCL With IRF4 Rearrangement | High-grade B-cell... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 PositiveUnited States